Amgen's Prolia receives FDA approval for new indications to treat cancer patients

[News]

Amgen today announced that the U.S. Food and Drug Administration (FDA) approved two new indications for Prolia® (denosumab) as a treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer and as a treatment to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for non-metastatic prostate cancer.

More... (http://www.news-medical.net/news/20110919/Amgens-Prolia-receives-FDA-approval-for-new-indications-to-treat-cancer-patients.aspx)